All In Biotech

Drug Trial Radar · NCT06008925

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

A Dose Ascending, Open Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of VG161 Combined With Nivolumab Injection in Subjects With Metastatic Gastric Cancer

Last checked: Nov 20, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

43

Planned (sponsor's estimate)

Start

Nov 17, 2022

Primary completion

Dec 2025

Study completion Jun 2026

Sponsor

Sponsor type
Industry
First posted
Aug 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 injection. This study will be conducted in combination with nivolumab injection in HSV seropositive subjects with advanced metastatic gastric or gastroesophageal junction adenocarcinoma who have previously received two or more systemic treatment regimens (which must include anti-PD-1 monoclonal antibodies). This is an open-label study divided into two parts. Part 1: This part is an escalating dose trial to explore the safety of the combination and determine the recommended safe dose of the combination. Part 2: This part is an extension trial to investigate the preliminary efficacy of the combination at a safe dose.

Conditions

  • Metastatic Gastric Cancer

Interventions

  • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))Drug

    Intratumoral injection only. Dosing days may be Day 1 or Days 1-3 only.

  • Nivolumab InjectionDrug

    Administered once at 3 mg/kg intravenously on Days 8 and 22 of each cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib:RP2D/MTDTime frame: through Phase Ib study completion, an average of 1 year
  2. Phase Ib:Incidence and number of DLTTime frame: through Phase Ib study completion, an average of 1 year
  3. Phase Ib and Phase IIa:AE, SAE occurrence and frequencyTime frame: through Phase Ib and Phase IIa study completion, an average of 2 year
  4. Phase IIa:ORRTime frame: through Phase IIa study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.